Valsartan increases circulating adiponectin levels without changing HOMA-IR in patients with type 2 diabetes mellitus and hypertension

Journal of International Medical Research

Volumn 38, Issue 1, 2010, Pages 234-241

  Lee, J M ^a   Kim, J H ^a   Son, H S ^a   Hong, E G ^b   Yu, J M ^b   Han, K A ^c   Min, K W ^c   Chang, Sang Ah ^a  

^a The Catholic University of Korea   (South Korea)

^b Hallym University   (South Korea)

^c Eulji University   (South Korea)

Author keywords

Adiponectin; Angiotensin II receptor blocker; Hypertension; Insulin sensitivity; Type 2 diabetes mellitus; Valsartan

Indexed keywords

ADIPONECTIN; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; GLINIDE; GLYCOSYLATED HEMOGLOBIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; SULFONYLUREA; UNCLASSIFIED DRUG; VALSARTAN;

ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC HYPERTENSION; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG EFFECT; FEMALE; HOMEOSTASIS; HORMONE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; METABOLIC PARAMETERS; MORNING DOSAGE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; SYSTOLIC BLOOD PRESSURE;

EID: 77749252450     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001003800128     Document Type: Article

References (26)

1. Berg AH, Coombs TP, Scherer PE: ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 2002; 13: 84-89.
2. Ouchi N, Kihara S, Arita Y, et al: Novel modulator for endothelial adhesion molecules: adipocyte derived plasma protein adiponectin. Circulation 1999; 100: 2473-2476.
3. Hotta K, Funahashi T, Arita Y, et al: Plasma concentrations of a novel, adipose specific protein, adiponectin in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 2000; 20: 1595-1599.
4. Okamoto Y, Kihara S, Funahashi T, et al: Adiponectin: a key adipocytokine in metabolic syndrome. Clin Sci (Lond) 2006; 110: 267-278.
5. Yenicesu M, Yilmas MI, Cagler K, et al: Blockade of the renin-angiotensin system increases plasma adiponectin levels in type 2 diabetic patients with proteinuria. Nephron Clin Pract 2005; 99: c115-c121.
6. Top C, Cingozbay BY, Terekeci H, et al: The effect of valsartan on insulin sensitivity in patients with primary hypertension. J Int Med Res 2002; 30: 15-20.
7. Furuhashi M, Ura N, Higashiura K, et al: Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 2003; 42: 76-81.
8. Arouz-Pacheco C, Parrott MA, Raskin P, et al: Treatment of hypertension in adults with diabetes. Diabetes Care 2003; 26(suppl 1): S80-S82.
9. Criscione L, Bradley WA, Buhlmayer P, et al: Valsartan: preclinical and clinical profile of an antihypertensive angiotensin II antagonist. Cardiovasc Drug Rev 1995; 13: 230-250.
10. American Diabetes Association: Diagnosis and classification of diabetes mellitus. Diabetes Care 2006; 29(suppl 1): S43-S48.
11. Chobanian AV, Barkis GL, Black HR, et al: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289: 2560-2572.
12. Yilmaz MI, Sonmez A, Caglar K, et al: Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology (Carlton) 2007; 12: 147-153.
13. Luna B, Hughes AT, Feinglos MN: The use of insulin secretagogues in the treatment of type 2 diabetes. Prim Care 1999; 26: 895-915.
14. Usui, I, Fujisaka S, Yamazaki K, et al: Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients. Diabetes Res Clin Pract 2007; 77: 210 - 214.
15. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique; a method for quantifying insulin secretion and resistance. Am J Physiol 1979; 237: E214-E223.
16. Tomiyama H, Motobe K, Zaydun G, et al: Insulin sensitivity and endothelial function in hypertension: a comparison of temocapril and candesartan. Am J Hypertens 2005; 18: 178-182.
17. Nowak L, Adamczak M, Wiecek A: Blockade of sympathetic nervous system activity by rilmenidine increases plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens 2005; 18: 1470-1475.
18. Koh KK, Quon MJ, Han SH, et al: Antiinflammatory and metabolic effects of candesartan in hypertensive patients. Int J Cardiol 2006; 108: 96-100.
19. Delles C, Raff U, Mimran A, et al: Effects of telmisartan and ramipril on adiponectin and blood pressure in patients with type 2 diabetes. Am J Hypertens 2008; 21: 1330-1336.
20. Celik T, Iyisoy A, Kursaklioglu H, et al: Comparative effects of nebivolol and metoprolol on oxidative stress, insulin resistance, plasma adiponectin and soluble Pselectin levels in hypertensive patients. J Hypertens 2006; 24: 591-596.
21. Yang WS, Lee WJ, Funahashi T, et al: Weight reduction increases plasma adiponectin levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001; 86: 3815-3819.
22. Janke J, Engeli S, Gorzelniak K, et al: Mature adipocytes inhibit in vitro differentiation of human preadipocytes via angiotensin type 1 receptors. Diabetes 2002; 51: 1699-1707.
23. Schling P, Loffler G: Effects of angiotensin II on adipose conversion and expression of genes of the renin-angiotensin system in human preadipocytes, Horm Metab Res 2001; 33: 189-195.
24. Kranzhofer R, Schmidt J, Pfeiffer CA, et al: Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999; 19: 1623-1629.
25. Dandona P, Kumar V, Aljada A, et al: Angiotensin II receptor blocker valsartan suppresses reactive oxygen species generation in leukocytes, nuclear factor-êB, in mononuclear cells of normal subjects: evidence of an anti-inflammatory action. J Clin Endocrinol Metab 2003; 88: 4496-4501.
26. Nomura S, Shouzu A, Omoto S, et al: Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. Thromb Res 2006; 117: 385-392.